+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Oncogenomics. Molecular Approaches to Cancer

  • ID: 2182465
  • Book
  • 400 Pages
  • John Wiley and Sons Ltd
1 of 3
Diagnoses termed "cancer" consist of hundreds of different diseases with as many constellations of genetic alterations. Genomic technologies have made it possible to identify all of the tumor–specific mutations, to profile individual tumors at the DNA, RNA, and protein levels, and to test in cellular and animal systems the responses of particular genotypes to particular drugs. Oncogenomics and allied disciplines have identified new targets for genotype–specific treatments and provided strategies to validate these targets and to develop drugs. With the potential need to stratify patients by genotype, clinical testing of targeted drugs has become more complicated while expectations of patients, investors, and funding agencies have become accelerated. Oncogenomics: Molecular Approaches to Cancer offers the first rigorous yet broadly accessible treatment of the impact of genomics on cancer research and care. Clearly written by world–renowned scientists in the field, and edited for overall cohesion, Oncogenomics progresses logically from molecular profiling to model systems, cancer pharmacology, and clinical trials. Oncogenomics
  • Covers cutting–edge issues such as array–based diagnostics, pharmaco–genomics, and molecularly targeted therapeutics
  • Includes discussions of ethical, legal, and social issues related to cancer genomics and clinical trials
  • Provides links to online oncogenomic resources and references

Recognizing the multidisciplinary character of Oncogenomics, the editors include an advanced introduction to cancer genetics and cancer pharmacology that makes accessible state–of–the–art topics such as expression profiling, SNPs in cancer, tissue microarrays, and chemical and genetic validation studies. Scientists, oncologists, and other healthcare professionals, as well as advanced students, will find Oncogenomics an essential resource for elucidating this exciting field.

Note: Product cover images may vary from those shown
2 of 3


Second I: Introduction.

1. At the Precarious Cusp of Oncogenomics (Charles Brenner).

Second II: Molecular Profiling in Cancer: DNA, RNA and Protein.

2. Genome–Wide Searches for Mutations in Human Cancer (Michael R. Stratton, P. Andrew Futreal, and Richard Wooster).

3. Molecular Cytogenetics: Increasing Resolution Using Array–Based CGH (Anne Kallioniemi).

4. SNPs and Functional Polymorphisms in Cancer (Penelope E. Bonnen and David L. Nelson).

5. Expression Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility (Therese Sørlie, Anne–Lise Børresen–Dale, Per E. Lønning, Patrick O. Brown, and David Botstein).

6. Classifying Hereditary Cancers and Phenocopies of Hereditary Cancers Using Expression Arrays (Mary B. Daly, Alicia Parlanti, and David Duggan).

7. Linking Drugs and Genes: Pharmacogenomics, Pharmacoproteomics, Bioinformatics, and the NCI–60 (John N. Weinstein).

8. Tissue Microanalysis: Profiling Cancer Stages (Michael A. Tangrea and Michael R. Emmert–Buck).

9. Proteomic s in Bladder Cancer (Julio E. Celis, Irina Gromova, Fritz Rank and Pavel Gromov).

Second III: Model Systems.

10. Chemical and Genetic Methods to Validate Targets in Nonmammalian Organisms (Tia M. Maiolatesi and Charles Brenner).

11. Mouse Models of Cancer (Debrah M. Thompson, Louise van der Weyden, Patrick J. Biggs, Yeun–Jun Chung and Allan Bradley).

12. Genome–Wide Modifier Screens: How the Genetics of Cancer Penetrance May Shape the Future of Prevention and Treatment (Linda D. Siracusa, Karen A. Silverman, Revati Koratkar, Marina Markova and Arthur M. Buchberg).

Second IV: Molecularly Targeted Drugs.

13. Protein Kinases as Targets in Cancer Therapy: Validated and Emerging Approaches (Paul Nghiem, Yong–son Kim and Stuart L. Schreiber).

14. Ras Superfamily–Directed Compounds (George C. Prendergast).

15. Clinomics: Post–Genomic Cancer Care (Daniel D. Von Hoff, Haiyong Han, and David Bearss).

Part V: Conclusion).

16. Oncogenomics and the NCI Director s Vision for 2015 (Andrew C. von Eschenbach).


Note: Product cover images may vary from those shown
3 of 3


4 of 3
Charles Brenner
David Duggan
Note: Product cover images may vary from those shown